Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans

Cytology-based screening has been a cornerstone of cervical cancer prevention for decades. Following extensive evidence demonstrating higher sensitivity and accuracy, lower variability and better reproducibility of human papillomavirus (HPV)-based screening compared with conventional or liquid-based...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical microbiology and infection Vol. 26; no. 5; p. 579
Main Authors:	Maver, P J, Poljak, M
Format:	Journal Article
Language:	English
Published:	England 01.05.2020
Subjects:	Alphapapillomavirus - isolation & purification Cervix Uteri - pathology Cervix Uteri - virology Early Detection of Cancer - methods Early Detection of Cancer - statistics & numerical data Early Detection of Cancer - trends Europe Female Health Plan Implementation - statistics & numerical data Health Plan Implementation - trends Humans Papillomavirus Infections - diagnosis Papillomavirus Infections - pathology Uterine Cervical Neoplasms - diagnosis Uterine Cervical Neoplasms - pathology Europe Screening Cervical cancer screening Human papillomavirus Primary HPV-based screening Implementation
ISSN:	1469-0691, 1469-0691
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Cytology-based screening has been a cornerstone of cervical cancer prevention for decades. Following extensive evidence demonstrating higher sensitivity and accuracy, lower variability and better reproducibility of human papillomavirus (HPV)-based screening compared with conventional or liquid-based cytology, recent European guidelines strongly recommend primary HPV-based screening over standard cytology-based screening. In addition, HPV-based screening offers the possibility of self-sampling and makes possible longer screening intervals in women with negative screening results. We summarize the current status of implementation of HPV-based screening in Europe, describe the real-life experience and challenges from countries already performing HPV-based screening, and briefly review immediate and long-term plans for screening implementation in selected European countries. Data were obtained from peer-reviewed literature, personal communication with experts and authorities involved in formulating national recommendations and practical guidelines, and relevant national websites. As of July 2019, the Netherlands and Turkey are the only European countries with fully implemented national HPV-based cervical cancer screening. Italy, Sweden and Finland have already implemented HPV-based screening in several regions, and several other countries are at various stages of implementation. Some countries are considering transitioning from cytology-based to HPV-based screening, but are struggling with the suboptimal performance of current population-based programmes. Implementation of HPV-based screening has resulted in higher colposcopy referral rates, but also higher detection rates of CIN3+ lesions and cervical cancers requiring immediate treatment. Cytology is mostly used as a triage test, although other strategies are under consideration in some countries. HPV-based screening is best suited in organized population-based screening settings. In 2019, cervical cancer screening policies across Europe vary greatly. Experience in countries with national and regional HPV-based screening already implemented is generally very positive. Urgent action is needed in many European countries, especially those with suboptimal opportunistic cytology-based cervical cancer screening.
AbstractList	Cytology-based screening has been a cornerstone of cervical cancer prevention for decades. Following extensive evidence demonstrating higher sensitivity and accuracy, lower variability and better reproducibility of human papillomavirus (HPV)-based screening compared with conventional or liquid-based cytology, recent European guidelines strongly recommend primary HPV-based screening over standard cytology-based screening. In addition, HPV-based screening offers the possibility of self-sampling and makes possible longer screening intervals in women with negative screening results. We summarize the current status of implementation of HPV-based screening in Europe, describe the real-life experience and challenges from countries already performing HPV-based screening, and briefly review immediate and long-term plans for screening implementation in selected European countries. Data were obtained from peer-reviewed literature, personal communication with experts and authorities involved in formulating national recommendations and practical guidelines, and relevant national websites. As of July 2019, the Netherlands and Turkey are the only European countries with fully implemented national HPV-based cervical cancer screening. Italy, Sweden and Finland have already implemented HPV-based screening in several regions, and several other countries are at various stages of implementation. Some countries are considering transitioning from cytology-based to HPV-based screening, but are struggling with the suboptimal performance of current population-based programmes. Implementation of HPV-based screening has resulted in higher colposcopy referral rates, but also higher detection rates of CIN3+ lesions and cervical cancers requiring immediate treatment. Cytology is mostly used as a triage test, although other strategies are under consideration in some countries. HPV-based screening is best suited in organized population-based screening settings. In 2019, cervical cancer screening policies across Europe vary greatly. Experience in countries with national and regional HPV-based screening already implemented is generally very positive. Urgent action is needed in many European countries, especially those with suboptimal opportunistic cytology-based cervical cancer screening. Cytology-based screening has been a cornerstone of cervical cancer prevention for decades. Following extensive evidence demonstrating higher sensitivity and accuracy, lower variability and better reproducibility of human papillomavirus (HPV)-based screening compared with conventional or liquid-based cytology, recent European guidelines strongly recommend primary HPV-based screening over standard cytology-based screening. In addition, HPV-based screening offers the possibility of self-sampling and makes possible longer screening intervals in women with negative screening results.BACKGROUNDCytology-based screening has been a cornerstone of cervical cancer prevention for decades. Following extensive evidence demonstrating higher sensitivity and accuracy, lower variability and better reproducibility of human papillomavirus (HPV)-based screening compared with conventional or liquid-based cytology, recent European guidelines strongly recommend primary HPV-based screening over standard cytology-based screening. In addition, HPV-based screening offers the possibility of self-sampling and makes possible longer screening intervals in women with negative screening results.We summarize the current status of implementation of HPV-based screening in Europe, describe the real-life experience and challenges from countries already performing HPV-based screening, and briefly review immediate and long-term plans for screening implementation in selected European countries.OBJECTIVESWe summarize the current status of implementation of HPV-based screening in Europe, describe the real-life experience and challenges from countries already performing HPV-based screening, and briefly review immediate and long-term plans for screening implementation in selected European countries.Data were obtained from peer-reviewed literature, personal communication with experts and authorities involved in formulating national recommendations and practical guidelines, and relevant national websites.SOURCESData were obtained from peer-reviewed literature, personal communication with experts and authorities involved in formulating national recommendations and practical guidelines, and relevant national websites.As of July 2019, the Netherlands and Turkey are the only European countries with fully implemented national HPV-based cervical cancer screening. Italy, Sweden and Finland have already implemented HPV-based screening in several regions, and several other countries are at various stages of implementation. Some countries are considering transitioning from cytology-based to HPV-based screening, but are struggling with the suboptimal performance of current population-based programmes. Implementation of HPV-based screening has resulted in higher colposcopy referral rates, but also higher detection rates of CIN3+ lesions and cervical cancers requiring immediate treatment. Cytology is mostly used as a triage test, although other strategies are under consideration in some countries.CONTENTAs of July 2019, the Netherlands and Turkey are the only European countries with fully implemented national HPV-based cervical cancer screening. Italy, Sweden and Finland have already implemented HPV-based screening in several regions, and several other countries are at various stages of implementation. Some countries are considering transitioning from cytology-based to HPV-based screening, but are struggling with the suboptimal performance of current population-based programmes. Implementation of HPV-based screening has resulted in higher colposcopy referral rates, but also higher detection rates of CIN3+ lesions and cervical cancers requiring immediate treatment. Cytology is mostly used as a triage test, although other strategies are under consideration in some countries.HPV-based screening is best suited in organized population-based screening settings. In 2019, cervical cancer screening policies across Europe vary greatly. Experience in countries with national and regional HPV-based screening already implemented is generally very positive. Urgent action is needed in many European countries, especially those with suboptimal opportunistic cytology-based cervical cancer screening.IMPLICATIONSHPV-based screening is best suited in organized population-based screening settings. In 2019, cervical cancer screening policies across Europe vary greatly. Experience in countries with national and regional HPV-based screening already implemented is generally very positive. Urgent action is needed in many European countries, especially those with suboptimal opportunistic cytology-based cervical cancer screening.
Author	Poljak, M Maver, P J
Author_xml	– sequence: 1 givenname: P J surname: Maver fullname: Maver, P J email: polona.maver@mf.uni-lj.si organization: Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia. Electronic address: polona.maver@mf.uni-lj.si – sequence: 2 givenname: M surname: Poljak fullname: Poljak, M email: mario.poljak@mf.uni-lj.si organization: Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Zaloška 4, 1000 Ljubljana, Slovenia. Electronic address: mario.poljak@mf.uni-lj.si
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31539637$$D View this record in MEDLINE/PubMed
BookMark	eNpNkE9LxDAUxIOsuH_0A3iRHD3Y-pK02cabLKsrLLgH9VrS5HXN0qa1aQW_vYVdQRiY32F4vJk5mfjGIyHXDGIGTN4fYlO7mANTMYwCeUZmLJEqAqnY5B9PyTyEAwBwIZILMhUsFUqK5Ywcdp2rdfdDN7uPqNABLTXYfTujK2q0H5kG0yF65_fUeboeuqbFB-rqtsIafa9713gaRh_CHTWfuqrQ73Fk7S0th37okLaV9uGSnJe6Cnh18gV5f1q_rTbR9vX5ZfW4jUzCVB_Z1JhlIW1WIpYqNWNTk1krIQFZGIGiMCXyRKg05WhtorIS1FKnWslMAWR8QW6Pd9uu-Row9HntgsFq_AGbIeScqzTJlqDUGL05RYeiRpu3xzHyv334L2qIaz4
CitedBy_id	crossref_primary_10_1186_s13027_023_00555_2 crossref_primary_10_1016_j_jcv_2022_105237 crossref_primary_10_1016_j_ygyno_2021_06_010 crossref_primary_10_1002_cam4_6740 crossref_primary_10_1002_jmv_70273 crossref_primary_10_3389_fonc_2023_1144672 crossref_primary_10_1002_ijc_35222 crossref_primary_10_1002_cam4_70299 crossref_primary_10_1002_ijc_33320 crossref_primary_10_1186_s13027_025_00675_x crossref_primary_10_2807_1560_7917_ES_2025_30_28_2400689 crossref_primary_10_3390_cancers13225737 crossref_primary_10_1002_jmv_29271 crossref_primary_10_1136_bmjph_2024_001565 crossref_primary_10_1016_j_ygyno_2023_11_036 crossref_primary_10_1002_jmv_28583 crossref_primary_10_1016_j_hpr_2024_300756 crossref_primary_10_1136_bmjopen_2019_034483 crossref_primary_10_1007_s10096_024_04963_z crossref_primary_10_1097_CEJ_0000000000000701 crossref_primary_10_1097_MD_0000000000027177 crossref_primary_10_1016_j_heliyon_2024_e31061 crossref_primary_10_1016_j_ajog_2025_02_029 crossref_primary_10_1016_j_jddst_2022_103351 crossref_primary_10_3322_caac_21696 crossref_primary_10_1002_ijc_33851 crossref_primary_10_1002_ijc_35359 crossref_primary_10_1002_jmv_70561 crossref_primary_10_1016_j_bios_2023_115968 crossref_primary_10_1371_journal_pone_0306044 crossref_primary_10_1016_j_jcv_2024_105649 crossref_primary_10_17650_1994_4098_2025_21_1_86_105 crossref_primary_10_1002_cncy_22916 crossref_primary_10_1016_j_ypmed_2020_106293 crossref_primary_10_1002_ijgo_13865 crossref_primary_10_3390_cancers14112612 crossref_primary_10_1093_oncolo_oyaf197 crossref_primary_10_3390_cancers15205095 crossref_primary_10_1002_ijc_33850 crossref_primary_10_1371_journal_pmed_1004505 crossref_primary_10_1007_s00418_023_02230_4 crossref_primary_10_31832_smj_1669557 crossref_primary_10_1155_2023_9676206 crossref_primary_10_1016_j_heliyon_2023_e14289 crossref_primary_10_7326_M21_4372 crossref_primary_10_3390_diagnostics12020403 crossref_primary_10_1155_2022_5054507 crossref_primary_10_3390_medicina60030364 crossref_primary_10_1016_j_cmi_2021_04_031 crossref_primary_10_3390_ai5040144 crossref_primary_10_3390_curroncol32070407 crossref_primary_10_1016_j_lfs_2021_120202 crossref_primary_10_1038_s41416_021_01614_4 crossref_primary_10_1177_10732748251336414 crossref_primary_10_7554_eLife_76070 crossref_primary_10_1111_aogs_14121 crossref_primary_10_3390_diagnostics12061508 crossref_primary_10_1016_j_ejogrb_2020_12_061 crossref_primary_10_1016_j_gaceta_2025_102522 crossref_primary_10_3390_life10110290 crossref_primary_10_1002_cncr_34899 crossref_primary_10_1016_j_ygyno_2021_01_005 crossref_primary_10_3390_molecules28062502 crossref_primary_10_1186_s12879_022_07893_3 crossref_primary_10_1002_jmv_28482 crossref_primary_10_4103_joc_joc_108_23 crossref_primary_10_1371_journal_pmed_1004253 crossref_primary_10_1371_journal_pmed_1004372 crossref_primary_10_1016_j_clon_2021_06_013 crossref_primary_10_2478_raon_2021_0043 crossref_primary_10_1002_jmv_70022 crossref_primary_10_1016_j_ygyno_2021_06_020 crossref_primary_10_3390_pathogens13040312 crossref_primary_10_1002_jmv_29500 crossref_primary_10_1016_j_eurox_2024_100360 crossref_primary_10_1097_JS9_0000000000000516 crossref_primary_10_1111_bjhp_12688 crossref_primary_10_3390_cancers16091621 crossref_primary_10_1002_ijc_34441 crossref_primary_10_1002_cncy_22303 crossref_primary_10_1016_j_modpat_2025_100742 crossref_primary_10_1002_ijgo_70277 crossref_primary_10_1093_eurpub_ckad225 crossref_primary_10_1177_20552076251331893 crossref_primary_10_1128_jcm_01403_22 crossref_primary_10_1002_cam4_70620 crossref_primary_10_1002_agt2_70008 crossref_primary_10_1186_s12905_024_03186_w crossref_primary_10_1016_j_jcv_2024_105671 crossref_primary_10_3390_pharmaceutics13122192 crossref_primary_10_3802_jgo_2025_36_e81 crossref_primary_10_1080_14796694_2024_2409625 crossref_primary_10_1097_CEJ_0000000000000856 crossref_primary_10_1111_aogs_14707 crossref_primary_10_3390_healthcare10071325 crossref_primary_10_1002_ijc_33128 crossref_primary_10_3390_diagnostics15162066 crossref_primary_10_1186_s12916_025_04149_0 crossref_primary_10_7759_cureus_31399 crossref_primary_10_15388_Amed_2022_29_1_18 crossref_primary_10_1002_jmv_28417 crossref_primary_10_3390_app13021061 crossref_primary_10_1016_S1470_2045_21_00058_9 crossref_primary_10_3390_v16030416 crossref_primary_10_1128_JCM_00286_21 crossref_primary_10_1038_s41416_024_02681_z crossref_primary_10_3390_ijms252413271 crossref_primary_10_1128_spectrum_01631_22 crossref_primary_10_1158_1940_6207_CAPR_25_0029 crossref_primary_10_1016_j_jcv_2021_104851 crossref_primary_10_1111_jog_15784 crossref_primary_10_7759_cureus_50907 crossref_primary_10_1007_s10147_020_01727_5 crossref_primary_10_3390_diagnostics15091176 crossref_primary_10_1002_ijc_34170 crossref_primary_10_1055_s_0043_1772483 crossref_primary_10_3390_jmp4020008 crossref_primary_10_4014_jmb_2304_04009 crossref_primary_10_1016_j_eimce_2022_08_001 crossref_primary_10_3892_ol_2022_13233 crossref_primary_10_2196_58066 crossref_primary_10_1016_j_jmoldx_2024_05_012 crossref_primary_10_3390_v14050893 crossref_primary_10_26633_RPSP_2023_72 crossref_primary_10_2196_38917 crossref_primary_10_1002_ijc_34504 crossref_primary_10_1111_aogs_14311 crossref_primary_10_1002_dc_25021 crossref_primary_10_1002_jmv_29521 crossref_primary_10_1371_journal_pone_0313004 crossref_primary_10_7759_cureus_41098 crossref_primary_10_1002_dc_25146 crossref_primary_10_1186_s13027_025_00688_6 crossref_primary_10_1186_s12916_021_02026_0 crossref_primary_10_1016_j_ijbiomac_2025_143468 crossref_primary_10_1016_j_ygyno_2022_07_023 crossref_primary_10_1002_ijc_34519 crossref_primary_10_1097_GME_0000000000002222 crossref_primary_10_3390_bios13020202 crossref_primary_10_1371_journal_pone_0296107 crossref_primary_10_1158_1940_6207_CAPR_21_0104 crossref_primary_10_1016_j_jcv_2024_105734 crossref_primary_10_1080_14737159_2020_1835472 crossref_primary_10_1016_j_puhe_2024_04_036 crossref_primary_10_2147_CMAR_S360712 crossref_primary_10_1177_09691413231158932 crossref_primary_10_1002_ijc_33820 crossref_primary_10_1002_jmv_29649 crossref_primary_10_1016_j_jcv_2024_105737 crossref_primary_10_1186_s12889_023_17293_0 crossref_primary_10_1002_cncy_22624 crossref_primary_10_1016_j_molmed_2024_05_009 crossref_primary_10_1111_apm_13265 crossref_primary_10_1016_j_puhe_2023_11_026 crossref_primary_10_1016_j_jcvp_2021_100055 crossref_primary_10_1016_j_medp_2025_100082 crossref_primary_10_1186_s43058_021_00211_z crossref_primary_10_1007_s12672_025_02936_y crossref_primary_10_1007_s10552_023_01677_z crossref_primary_10_1186_s12905_023_02215_4 crossref_primary_10_1002_ijc_35289 crossref_primary_10_1038_s41598_022_22438_z crossref_primary_10_1136_jclinpath_2021_208054 crossref_primary_10_1016_j_ejogrb_2024_06_030 crossref_primary_10_1097_LGT_0000000000000852 crossref_primary_10_1089_jwh_2020_8918 crossref_primary_10_1002_ijc_70134 crossref_primary_10_3390_cancers16071322 crossref_primary_10_1093_eurpub_ckae075 crossref_primary_10_1093_hmg_ddaf027 crossref_primary_10_1016_j_ijid_2021_05_064 crossref_primary_10_3389_fpubh_2022_987787 crossref_primary_10_1155_2022_3997562 crossref_primary_10_1007_s12672_025_02432_3 crossref_primary_10_3389_frhs_2025_1595934 crossref_primary_10_3390_tropicalmed8120511 crossref_primary_10_1186_s12905_023_02423_y crossref_primary_10_3390_cancers16173022 crossref_primary_10_1002_mco2_70203 crossref_primary_10_1002_ijc_34804 crossref_primary_10_1186_s12905_022_01851_6 crossref_primary_10_1016_j_jasc_2024_09_003 crossref_primary_10_3390_diagnostics13243612 crossref_primary_10_1016_j_pathol_2021_08_003 crossref_primary_10_1016_j_aca_2025_344353 crossref_primary_10_1186_s12913_023_10040_6 crossref_primary_10_1016_j_jiph_2024_04_020 crossref_primary_10_3390_cancers15174412 crossref_primary_10_3390_jpm13020161 crossref_primary_10_1002_dc_24633 crossref_primary_10_1186_s12885_024_13050_7 crossref_primary_10_1186_s12879_024_09827_7
ContentType	Journal Article
Copyright	Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Copyright_xml	– notice: Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.cmi.2019.09.006
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Biology
EISSN	1469-0691
ExternalDocumentID	31539637
Genre	Journal Article Review
GeographicLocations	Europe
GeographicLocations_xml	– name: Europe
GroupedDBID	--- --M .3N .GA .Y3 05W 0R~ 0SF 10A 1OC 29B 2WC 31~ 36B 3V. 4.4 457 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6I. 6J9 702 7PT 7X7 8-0 8-1 8-3 8-4 8-5 88E 8C1 8FE 8FH 8FI 8FJ 8FQ 8R4 8R5 8UM 930 A01 A03 A8Z AACTN AAEDW AAFTH AAHHS AAIKJ AALRI AANHP AAONW AAXUO ABCQN ABDBF ABEML ABJNI ABMAC ABOCM ABUWG ABVKL ACBWZ ACCFJ ACGFO ACGFS ACPRK ACRPL ACSCC ACUHS ACXQS ACYXJ ADBBV ADEZE ADNMO ADVLN ADZOD AEEZP AENEX AEQDE AEUYN AEXQZ AFBPY AFEBI AFETI AFJKZ AFKRA AFRAH AFTJW AFZJQ AGHFR AHEFC AHMBA AITUG AIWBW AJAOE AJBDE AKRWK ALIPV ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZBYB AZFZN BAFTC BAWUL BBNVY BDRZF BENPR BHPHI BPHCQ BVXVI BY8 CAG CCPQU CGR COF CS3 CUY CVF D-6 D-7 D-E D-F DCZOG DIK DR2 DWQXO E3Z EAD EAP EBC EBD EBS ECM EDH EIF EJD EMB EMK EMOBN ESX EX3 F00 F01 F04 F5P FDB FEDTE FIJ FYUFA G-S G.N GI5 GODZA H.X HCIFZ HF~ HMCUK HOLLA HVGLF HZI HZ~ IHE IX1 IXB J0M K48 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M1P M3C M3G M41 M7P MK4 MM. N04 N05 N9A NCXOZ NF~ NPM O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PQQKQ PROAC PSQYO Q.N Q11 Q2X QB0 R.K ROL RWL RX1 RXW SSZ SUPJJ SV3 TAE TEORI TUS UB1 UKHRP V8K V9Y W8V W99 WOW WQJ WRC WXI WYUIH X6Y XG1 YFH ~IA ~WT 7X8 AAYWO ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP APXCP EFKBS WIN
ID	FETCH-LOGICAL-c419t-d5cc7b6d8feef95c101c8dd60406bc3e3bcfe2439552edd498f097a5a96890082
IEDL.DBID	7X8
ISICitedReferencesCount	226
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000532069100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1469-0691
IngestDate	Wed Oct 01 14:24:26 EDT 2025 Wed Feb 19 02:29:48 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	5
Keywords	Screening Cervical cancer screening Human papillomavirus Primary HPV-based screening Implementation
Language	English
License	Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c419t-d5cc7b6d8feef95c101c8dd60406bc3e3bcfe2439552edd498f097a5a96890082
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
PMID	31539637
PQID	2295487099
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2295487099 pubmed_primary_31539637
PublicationCentury	2000
PublicationDate	2020-May 20200501
PublicationDateYYYYMMDD	2020-05-01
PublicationDate_xml	– month: 05 year: 2020 text: 2020-May
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Clinical microbiology and infection
PublicationTitleAlternate	Clin Microbiol Infect
PublicationYear	2020
SSID	ssj0002334
Score	2.661809
SecondaryResourceType	review_article
Snippet	Cytology-based screening has been a cornerstone of cervical cancer prevention for decades. Following extensive evidence demonstrating higher sensitivity and...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	579
SubjectTerms	Alphapapillomavirus - isolation & purification Cervix Uteri - pathology Cervix Uteri - virology Early Detection of Cancer - methods Early Detection of Cancer - statistics & numerical data Early Detection of Cancer - trends Europe Female Health Plan Implementation - statistics & numerical data Health Plan Implementation - trends Humans Papillomavirus Infections - diagnosis Papillomavirus Infections - pathology Uterine Cervical Neoplasms - diagnosis Uterine Cervical Neoplasms - pathology
Title	Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans
URI	https://www.ncbi.nlm.nih.gov/pubmed/31539637 https://www.proquest.com/docview/2295487099
Volume	26
WOSCitedRecordID	wos000532069100010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UqnjxUV_1xQoeXcx7d72IiKUHW3LQ0lvJPgIRm9amFfz3zu4m9CQIXkIuC2Fm9ptvHplB6CbzYxExTonQIocARQAO-qEmWshQs9hTvk24DV_oYMBGI57WCbeqbqtsMNECtZpKkyO_M2ungVwDoXmYfRKzNcpUV-sVGuuoFQKVMVZNR6tp4UHoqsoQAhIv4X5T1bT9XXJSmM4ubsecesnvDNN6mu7ef79xH-3WHBM_OqM4QGu6bKMtt3Xyu422-3U9_RC9p27YBO6lQ2IcmsLSggccl8Ye5hhgBUJdcHC4KLHL3d_jYtK0nRu9YvNX0rK6xbLZzALvWamwG1iCZx_gD4_QW_f59alH6u0LREY-XxAVS0lFoliudc5jCWKTTKkEbn1iFBkKmesA-EwcB1qpiLPc4zSLM54wbpjFMdoop6U-RZgJ7YUZBHaxAYwISEmkJJeKBjLTYUQ76LqR5xis25QsslJPl9V4JdEOOnFKGc-cZMYhgDXABz37w-lztBOYQNl2Kl6gVg53W1-iTfm1KKr5lTUbeA7S_g80Uc1A
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Primary+HPV-based+cervical+cancer+screening+in+Europe%3A+implementation+status%2C+challenges%2C+and+future+plans&rft.jtitle=Clinical+microbiology+and+infection&rft.au=Maver%2C+P+J&rft.au=Poljak%2C+M&rft.date=2020-05-01&rft.issn=1469-0691&rft.eissn=1469-0691&rft.volume=26&rft.issue=5&rft.spage=579&rft_id=info:doi/10.1016%2Fj.cmi.2019.09.006&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1469-0691&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1469-0691&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1469-0691&client=summon